BLRX — BioLineRx Ltd.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1498403 · Israel
Last close
$1.12
Market Cap
$5.43M
52W High
$3.95
52W Low
$1.12
ADV30
13,356
Next earnings
2026-11-23

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 294,000 235,000 -3,573,000 -3,026,000 33,480,000 4,627,000 16,861,000
Mar 2026 477,000 382,000 -3,004,000 -1,601,000 38,797,000 2,504,000 17,962,000
Dec 2025 194,000 154,000 -3,386,000 -1,385,000 40,905,000 3,250,000 17,560,000
Sep 2025 427,000 343,000 -2,207,000 -977,000 39,804,000 7,914,000 20,271,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-10,803,000
Investing CF
$12,387,000
Financing CF
$-4,488,000
CapEx
$-6,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.00
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-405,629,000
Inventory
$2,167,000
Receivables
$728,000
ST Investments
$8,451,000
EBIT TTM
$-9,127,000
Pretax Income TTM
$-10,140,000
Interest Exp TTM
$1,013,000
Analysts
2

Yahoo Snapshot (yfinance, live)

Total Revenue
$1,392,000
EBITDA
$-12,118,000
Free Cash Flow
$-8,852,375
Enterprise Value
$8,676,421
Total Cash
$13,078,000
Total Debt
$7,941,000
Shares Out
4,848,991
Trailing EPS
$0.00
Book Value
$3.00
ROE
-55.3%
ROA
-19.8%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 1,180,000 -10,287,000 -1,175,000 40,905,000 17,560,000 18,196,000 -8,074,000
Dec 2024 28,940,000 -19,152,000 -9,221,000 38,906,000 25,445,000 13,461,000 -43,873,000
Dec 2023 4,800,000 -42,991,000 -60,614,000 63,925,000 50,702,000 13,223,000 -22,608,000
Dec 2022 0 -29,157,000 -24,951,000 76,384,000 25,543,000 50,841,000 -26,240,000

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.52

Peers — same industry

TickerNameMarket CapLastDaily %
ALZN Alzamend Neuro, Inc. $5.45M $1.13 —
INBP INTEGRATED BIOPHARMA INC $5.59M $0.18 —
AEON AEON Biopharma, Inc. $5.66M $0.11 —
OTLC Oncotelic Therapeutics, Inc. $5.72M $0.01 —
GTBP GT Biopharma, Inc. $5.74M $3.18 —

News headlines (Yahoo Finance, 1h cache)

BioLineRx to Report Third Quarter 2026 Results on November 23, 2026
2026-11-18 14:00 · Yahoo
BioLineRx Enters into $5.6 Million Royalty Monetization Transaction with Soleus Capital
2026-11-18 12:00 · Yahoo
BioLineRx and Hemispherian Present Phase 1/2a Clinical Study and Pre-Clinical Updates, Including Brain PK/PD Data, at SNO 2026
2026-11-16 12:00 · Yahoo
BioLineRx and Hemispherian Present Preclinical Data Demonstrating Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancer at ESMO 2026
2026-10-23 11:00 · Yahoo
BioLineRx and Hemispherian Announce Two GLIX1 Presentations at the 31st Society for Neuro-Oncology (SNO) Annual Meeting & Education Day
2026-10-08 11:00 · Yahoo
BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026)
2026-09-10 11:00 · Yahoo
BLRX: New GLIX1 Data Touts Synergies
2026-09-01 12:05 · Yahoo
BioLine Rx Ltd (BLRX) (Q2 2026) Earnings Call Highlights: Advancing GLIX1 Pipeline and ...
2026-08-31 21:00 · Yahoo
BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update
2026-08-31 11:00 · Yahoo
BioLineRx to Report Second Quarter 2026 Results on August 31, 2026
2026-08-25 11:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.